Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults

Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults

Background: Shigellosis accounts for substantial morbidity and mortality worldwide and is the second most common cause of moderate and severe diarrhoea in children. Methods: This phase 2b study (NCT03527173), conducted between August 2018 and November 2019, evaluated vaccine efficacy (VE), safety, a...

Full description

Bibliographic Details
Main Authors: Robert W. Frenck, Jr, Valentino Conti, Pietro Ferruzzi, Augustin G.W. Ndiaye, Susan Parker, Monica Malone McNeal, Michelle Dickey, Juan Paolo Granada, Giulia Luna Cilio, Iris De Ryck, Francesca Necchi, Akamol E. Suvarnapunya, Omar Rossi, Alessandra Acquaviva, Lakshmi Chandrasekaran, Kristen A. Clarkson, Joachim Auerbach, Elisa Marchetti, Robert W. Kaminski, Francesca Micoli, Rino Rappuoli, Allan Saul, Laura B. Martin, Audino Podda
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:EClinicalMedicine
Subjects:
Shigella sonnei
1790GAHB vaccine
GMMA
Human challenge study
Controlled human infection model
Shigellosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021003564

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021003564

Similar Items